Study of ctDNA in PTLD after transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of PTLD called CD20+ and it must be confirmed by biopsy.
- You must be at least 15 years old.
- You must have at least one lymph node that is 1.5 cm or larger on a scan.
- You must have a PET or CT scan within the last 28 days.
- You must have acceptable liver, kidney, and heart function as judged by your doctor.
- You cannot have already had chemotherapy for PTLD or have lymphoma in your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
This trial tests a combination of two immunotherapy drugs (loncastuximab tesirine and rituximab) to treat a type of lymphoma (blood cancer) that develops after solid organ transplantation. The goal is to see if this treatment can help control the cancer while being safe for transplant patients.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.